Day One Biopharma CEO awarded options, RSUs

Day One Biopharmaceuticals reported new equity awards to its Chief Executive Officer Jeremy Bender.

Rhea-AI Filing Summary

Day One Biopharmaceuticals reported new equity awards to its Chief Executive Officer Jeremy Bender. On January 30, 2026, he received a stock option for 355,000 shares of common stock at an exercise price of $11.16 per share, expiring on January 29, 2036. The option vests in equal monthly installments of 1/48th of the total from February 28, 2026, as long as he continues serving the company.

He was also granted 237,000 Restricted Stock Units (RSUs), each representing one share of common stock upon settlement. These RSUs vest in 1/16th increments on February 15, May 15, August 15 and November 15 in quarterly installments, contingent on continued service. The RSUs do not have a traditional expiration date; they either vest on schedule or are canceled if conditions are not met.

Insider Trade Summary

Grant/Award: 592,000 shares

Grant/Award 2 txns

Insider Bender Jeremy

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy Common Stock)	355,000	$0.00	$0.00
Grant/Award	Restricted Stock Units	237,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy Common Stock) — 355,000 contracts (Direct); Restricted Stock Units — 237,000 contracts (Direct)

Footnotes (4)

1. F1. The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
3. F3. The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4. F4. RSUs do not expire; they either vest or are canceled prior to the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did DAWN grant to its CEO Jeremy Bender?

Day One Biopharmaceuticals granted its CEO Jeremy Bender a stock option for 355,000 shares and 237,000 RSUs. The option has a fixed exercise price, while each RSU converts into one share of common stock upon vesting and settlement.

What are the terms of Jeremy Bender's 355,000 DAWN stock options?

The CEO received 355,000 stock options with an exercise price of $11.16 per share, expiring on January 29, 2036. These options vest monthly in 1/48th increments starting February 28, 2026, subject to his continued service.

How do the 237,000 DAWN RSUs granted to the CEO vest?

The 237,000 RSUs vest in 1/16th quarterly installments on February 15, May 15, August 15 and November 15. Vesting is contingent on Jeremy Bender continuing to provide service to Day One Biopharmaceuticals on each scheduled vesting date.

Do the DAWN RSUs granted to the CEO expire?

The RSUs granted to the CEO do not have a traditional expiration date. According to the terms, they either vest according to schedule or are canceled before the vesting date if the required service conditions are not satisfied.

How many DAWN derivative securities does the CEO hold after these grants?

Following the reported grants, Jeremy Bender holds 355,000 stock options and 237,000 RSUs as derivative securities. Both awards are reported as held directly, reflecting equity-based compensation tied to his ongoing service with the company.

What role does Jeremy Bender hold at Day One Biopharmaceuticals (DAWN)?

Jeremy Bender serves as both a Director and the Chief Executive Officer of Day One Biopharmaceuticals. The reported stock option and RSU awards represent part of his equity compensation in these leadership roles at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 05:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bender Jeremy

(Last) (First) (Middle)

1800 SIERRA POINT PARKWAY, SUITE 200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Day One Biopharmaceuticals, Inc. [ DAWN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	$11.16	01/30/2026		A		355,000		(1)	01/29/2036	Common Stock	355,000	$0	355,000	D
Restricted Stock Units	(2)	01/30/2026		A		237,000		(3)	(4)	Common Stock	237,000	$0	237,000	D

Explanation of Responses:

1. The option vests as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

3. The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

4. RSUs do not expire; they either vest or are canceled prior to the vesting date.

	/s/ Charles N. York II, as Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.